The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

Gene Therapy

Volumn 9, Issue 1, 2002, Pages 75-80

  Chung, S M ^a   Advani, S J ^a   Bradley, J D ^a   Kataoka, Y ^a   Vashistha, K ^a   Yan, S Y ^a   Markert, J M ^a   Gillespie, G Y ^a   Whitley, R J ^a   Roizman, B ^a   Weichselbaum, R R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Gene therapy; HSV

Indexed keywords

HERPES SIMPLEX VACCINE; ONCOLYTIC VIRUS; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; LIVER CELL CARCINOMA; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 0036169306     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj/gt/3301620     Document Type: Article

References (28)

1. Experimental therapy of human glioma by means of a genetically engineered virus mutant
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. Reovirus therapy of tumors with activated Ras pathway
4. Treatment of malignant gliomas using ganciclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant
5. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas
6. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
7. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors
8. 1 34.5, a gene non-essential for growth in culture
9. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
10. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
11. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
12. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro
13. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)
14. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
15. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
16. Replication-competent nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
17. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
18. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model
19. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
20. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus
21. Genetically engineered HSV in the treatment of glioma: A review
22. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial
23. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
24. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
25. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma
26. Radiogenetic therapy: On the interaction of viral therapy and ionizing radiation for improving local control of tumors
27. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
28. Spatial and temporal control of gene therapy using ionizing radiation